Literature DB >> 8644862

Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.

I C Le Poole1, R M van den Wijngaard, W Westerhof, P K Das.   

Abstract

Evidence for the involvement of cellular immunity in the etiopathogenesis of the hypopigmentary disorder vitiligo is provided by rare cases of inflammatory vitiligo. Nonlesional, perilesional, and lesional skin biopsies from three inflammatory vitiligo patients were immunohistochemically analyzed. The composition of inflammatory infiltrates present in perilesional skin was analyzed by antibodies to T cells (CD2, CD3, CD4, and CD8), Langerhans cells (CD1a), and macrophages (CD36 and CD68). The presence of activation markers on inflammatory cells was evaluated by analysis of HLA-DR, interleukin-2 receptor, and HECA452 expression. The presence or absence of melanocytes was determined by the antibody NKI-beteb. Moreover, the abundance of matrix molecule tenascin was semi-quantified using T2H5. Results indicate that within perilesional skin, epidermis-infiltrating T cells exhibit an increased CD8/CD4 ratio and increased cutaneous lymphocyte antigen and interleukin-2 receptor expression. These cells are frequently juxtapositionally apposed to remaining melanocytes. In perilesional dermis, CD68+OKM5- macrophages were more numerous than in lesional or nonlesional skin. Keratinocytes as well as melanocytes consistently express major histocompatibility complex class II antigens along stretches of basal and suprabasal layers in perilesional epidermis. Moreover, inflammation is accompanied by increased tenascin content. Although these observations do not permit differentiation between the immune infiltrates being a result as opposed to the cause of the disease process, results presented in this study are very suggestive of involvement of local immune reactivity in melanocyte destruction.

Entities:  

Mesh:

Year:  1996        PMID: 8644862      PMCID: PMC1861531     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  [Vitiligo with a raised inflammatory border].

Authors:  W R BUCKLEY; W C LOBITZ
Journal:  AMA Arch Derm Syphilol       Date:  1953-03

2.  Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin.

Authors:  J D Bos; C Hagenaars; P K Das; S R Krieg; W J Voorn; M L Kapsenberg
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

3.  Nonsegmental vitiligo: decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation.

Authors:  M B Abdel-Naser; W D Ludwig; H Gollnick; C E Orfanos
Journal:  Int J Dermatol       Date:  1992-05       Impact factor: 2.736

4.  On the etiology of vitiligo and gray hair.

Authors:  A B Lerner
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

5.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; K Sakaguchi; E Appella; J R Yannelli; G J Adema; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

7.  Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo.

Authors:  M B Abdel-Naser; S Krüger-Krasagakes; K Krasagakis; H Gollnick; A Abdel-Fattah; C E Orfanos
Journal:  Pigment Cell Res       Date:  1994-02

8.  Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo.

Authors:  R Harning; J Cui; J C Bystryn
Journal:  J Invest Dermatol       Date:  1991-12       Impact factor: 8.551

9.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Authors:  A B Bakker; M W Schreurs; A J de Boer; Y Kawakami; S A Rosenberg; G J Adema; C G Figdor
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

10.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  60 in total

Review 1.  Hypopigmentary skin disorders: current treatment options and future directions.

Authors:  Anke Hartmann; Eva-B Bröcker; Jürgen C Becker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.

Authors:  Richard A Spritz
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

3.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

4.  4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.

Authors:  Tara M Kroll; Hemamalini Bommiasamy; Raymond E Boissy; Claudia Hernandez; Brian J Nickoloff; Ruben Mestril; I Caroline Le Poole
Journal:  J Invest Dermatol       Date:  2005-04       Impact factor: 8.551

5.  Epidermal permeability barrier recovery is delayed in vitiligo-involved sites.

Authors:  J Liu; W Y Man; C Z Lv; S P Song; Y J Shi; P M Elias; M Q Man
Journal:  Skin Pharmacol Physiol       Date:  2010-02-25       Impact factor: 3.479

Review 6.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

7.  Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.

Authors:  Kirsten C Webb; Jonathan M Eby; Vidhya Hariharan; Claudia Hernandez; Rosalie M Luiten; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2014-07-10       Impact factor: 3.960

Review 8.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

9.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Authors:  Mehdi Rashighi; Priti Agarwal; Jillian M Richmond; Tajie H Harris; Karen Dresser; Ming-Wan Su; Youwen Zhou; April Deng; Christopher A Hunter; Andrew D Luster; John E Harris
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

10.  Mutant HSP70 reverses autoimmune depigmentation in vitiligo.

Authors:  Jeffrey A Mosenson; Andrew Zloza; John D Nieland; Elizabeth Garrett-Mayer; Jonathan M Eby; Erica J Huelsmann; Previn Kumar; Cecele J Denman; Andrew T Lacek; Frederick J Kohlhapp; Ahmad Alamiri; Tasha Hughes; Steven D Bines; Howard L Kaufman; Andreas Overbeck; Shikhar Mehrotra; Claudia Hernandez; Michael I Nishimura; Jose A Guevara-Patino; I Caroline Le Poole
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.